allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including TREGZI. Available dosage form: kit.
Drug details
- Generic Name
- allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq
- Brand Names
- TREGZI
- Application Number
- BLA125868
- Sponsor
- Orca Biosystems Inc.
- NDC Codes
- 2
- Dosage Forms
- KIT
Indications and Usage
1 INDICATIONS AND USAGE TREGZI is indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease-free survival, in the treatment of adults with hematological malignancies. TREGZI™ is an allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cells and T cells indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival, in the treatment of adults with hematological malignancies. ( 1 )